Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m2.

Chantal MathieuParesh DandonaAndreas L BirkenfeldTroels Krarup HansenNayyar IqbalJohn XuEnrico RepettoMarkus Florian ScheererFredrik ThorenMoshe Phillip

Published in: Diabetes, obesity & metabolism (2020)

Compared with the pooled DEPICT population, the benefit/risk profile of adjunct dapagliflozin therapy was more favourable in individuals with type 1 diabetes with body mass index ≥27 kg/m2 because of the reduced risk of diabetic ketoacidosis in this population.

Keyphrases

body mass index
weight gain
type diabetes
physical activity
randomized controlled trial
stem cells
mesenchymal stem cells
cell therapy
weight loss
phase iii